Over the last two decades, a large number of mutations have been identified in sarcomeric proteins as a cause of hypertrophic, dilated or restrictive cardiomyopathy. Functional analyses of mutant proteins in vitro have revealed several important functional changes in sarcomeric proteins that might be primarily involved in the pathogenesis of each cardiomyopathy. Creation of transgenic or knock-in animals expressing mutant proteins in their hearts confirmed that these mutations in genes for sarcomeric proteins induced distinct types of cardiomyopathies and provided useful animal models to explore the molecular pathogenic mechanisms and potential therapeutics of cardiomyopathy in vivo. In this review, I discuss the functional consequences of mutations in different sarcomeric proteins found in hypertrophic, dilated and restrictive cardiomyopathies in conjunction with their effects on cardiac structure and function in vivo and their possible molecular and cellular mechanisms, which underlie the pathogenesis of these inherited cardiomyopathies.
Introduction
Cardiomyopathy is classified into four main forms, hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), restrictive cardiomyopathy (RCM) and arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C). 1 HCM and DCM increase myocardial mass with distinct patterns of ventricular remodeling. HCM produces ventricular wall thickening (i.e., hypertrophy), especially in the inter-ventricular septum, with decreases in ventricular chamber volumes. DCM produces a prominent increase in chamber volumes as well as ventricular wall thickening. In HCM, systolic function is increased or at least preserved, while diastolic function is impaired in part because of the hypertrophy itself, interstitial fibrosis, and/or myocyte disarray.
Diastolic dysfunction is thought to be responsible for symptoms of heart failure and premature sudden cardiac death of HCM patients. In contrast, DCM is characterized by systolic dysfunction, which often leads to heart failure requiring cardiac transplantation or sudden cardiac death. RCM is characterized by restrictive diastolic dysfunction (i.e., restrictive filling and reduced diastolic volume of either or both ventricles) with normal or near normal systolic function and wall thickness.
Since the discovery of an HCM-causing mutation in the gene for β myosin heavy chain (β-MyHC) at 1990, 2 more than 400 mutations that cause HCM, DCM and RCM have been found in the genes for proteins constituting the sarcomere of cardiac muscle, whereas no sarcomeric protein genes have been discovered to be responsible for ARVD/C ( Fig.1 and Table   1 ). Despite a great number of studies that have been done to elucidate the structure and function of normal sarcomeric proteins since the middle of the last century, it is still difficult to predict the exact functional consequences of mutations found in cardiomyopathies only from their This review focuses on the mutations in sarcomeric proteins, i.e., the thin and thick filament proteins, 3 titin, 4 and Z-disc proteins, 5 and their roles in the pathogenesis of cardiomyopathies.
Mutations in sarcolemmal transmembrane proteins, cytoskeletal proteins and nuclear envelope proteins are the other important causes of DCM and are being discussed elsewhere. Functional studies so far made strongly suggest that an increased Ca 2+ sensitivity of cardiac muscle contraction is involved in the pathogenesis of HCM associated with the cTnT mutations.
cTnT mutations in DCM
Kamisago et al. reported a deletion mutation in TNNT2, ΔK210, in two independent families, which is the first cTnT mutation identified to be responsible for familial primary DCM. 20 In a functional study we made, this mutation had a Ca
2+
-desensitizing effect on the force generation in skinned cardiac muscle fibers and the ATPase activity in cardiac myofibrils. 21 Other groups have reported basically the same findings, strongly suggesting that the decrease in the Ca 2+ -sensitivity of force generation might be a primary mechanism for the pathogenesis. The quartz-crystal microbalance revealed that this mutation increased the affinity of cTnT for α-tropomyosin. 24 The disease expression of R131W, R205L and D270N is similar to that of ΔK210 in severity, being characterized by early-onset phenotype, high incidence of sudden death and/or heart failure, and frequently observed cardiomegaly. 25 Functional studies show that reduced Ca 2+ sensitivity is a consistent property of these mutations.
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Knock-in mice in which three base-pairs coding for the residue K210 were deleted from endogenous TNNT2 genes using gene-targeting technology. The knock-in mice developed enlarged hearts and heart failure and showed a high incidence of premature sudden death, 27 closely recapitulating the clinical phenotypes of human patients. 20, 25 Skinned cardiac muscle fibers showed a decrease in Ca 2+ sensitivity of force generation, consistent with the previous in vitro study. 21 Oral administration of pimobendan, a Ca 2+ sensitizer, known to directly increase the Ca 2+ sensitivity of myofilaments, was found to reduce the heart size of mutant mice and markedly improve the life expectancy, strongly suggesting that Ca 2+ sensitizers, such as pimobendan, are beneficial for the treatment of DCM patients affected by this mutation.
Cardiac troponin I (cTnI)

cTnI mutations in HCM
Kimura et al. reported six mutations in the cTnI gene (TNNI3) that were associated with HCM. 28 Although the prevalence of cTnI mutations is less than that of cTnT mutations, currently 26 mutations have been identified ( interstitial fibrosis, with no significant cardiac hypertrophy. 30 Working heart preparations showed enhanced systolic function and impaired diastolic function. Skinned cardiac muscle fibers showed a significant increase in Ca 2+ sensitivity with maximum force depression. This mouse model showed a very early death at 13 to 17 days after birth in mice with mutant cTnI being incorporated into myofilament by approximately 50%.
cTnI mutation in DCM
An N-terminal mutation in cTnI, A2V, has been found to cause a rare case of DCM inherited in an autosomal "recessive" manner and this mutation impairs the interaction of cTnI with cTnT but not cTnC as demonstrated in a mammalian two-hybrid assay system. 31
cTnI mutations in RCM
Six missense mutations have been found in the patients with idiopathic RCM. 32 A mixed appearance of RCM and HCM in a family with D190G suggested that there might be a common molecular mechanism for the pathogeneses of RCM and HCM. Functional studies indicate that the six mutations increase the Ca 2+ sensitivity of force generation in skinned cardiac muscle fibers, with their effects being much greater than those of HCM-causing mutations in cTnI. 33, 34 NMR studies show that dramatic Ca
2+
-sensitizing effects are caused by an unexpectedly subtle structural perturbation in a small region within cTnI molecule. 
cTnC mutation in HCM
A missense mutation L29Q in the cTnC gene (TNNC1) was reported in an HCM patient with late onset of the disease. 35 An N-terminal small region containing the L29 residue interacts with an N-terminal small region containing Ser22/23 of cTnI, and this interaction is abolished upon phosphorylation of cTnI Ser22/23 by protein kinase A (PKA), leading to a decrease in the myofilament Ca 2+ sensitivity. 36 Schmidtmann et al. found that this mutation abolished the N-terminal interaction between cTnI and cTnC, leading to a loss of change in myofilament Ca 2+ sensitivity upon phosphorylation of cTnI by PKA. 37 
cTnC mutation in DCM
A missense mutation, G159D, in TNNC1 was found in a DCM family with a malignant phenotype. 25 
Tropomyosin
Striated muscle expresses two isoforms of tropomyosin (TM), αTM and βTM, encoded in different genes. Skeletal muscle expresses both isoforms, but cardiac muscle expresses mostly αTM isoform.
αTM mutations in HCM
Eleven missense mutations have been found in the αTM gene (TPM1) as a cause of HCM ( Transgenic mice expressing E54K mouse αTM showed variable phenotype depending on the copy number of transgene. 53 The mice with high-copy number all died within 1.5 months of age. In contrast, mice with moderate-copy number showed a relatively mild phenotype with a tendency of developing DCM after two months of age and starting dying by 4 to 6 months of age.
In skinned cardiac muscle preparations, both moderate-and high-copy transgenic mice demonstrated significant decreases in the Ca 2+ sensitivity, consistent with the in vitro studies, as well as a marked depression in maximum force/cross-sectional area.
Actin
Mammalian cells express six isoforms encoded in different genes, which can be classified into 3 main groups, α-, β-and γ -actins. Sarcomeric actins, α-cardiac and α-skeletal, are known to be co-expressed in myocardium.
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α-cardiac actin mutations in HCM
The α-cardiac actin gene (ACTC1) is a rare cause of HCM (1.5%) and seven missense mutations have been found (Table 1) . These mutations decreased the thermal stability of actin monomer and impaired the filament formation, suggesting that the inability to form myofilaments and/or the accumulation of aggregates could be one of the cellular pathological effects of ACTC1 mutations. [56] [57] [58] E99K reduced the sliding velocity and averaged force in an in vitro motility assay and decreased the affinity of actin for myosin, 58 suggesting that impaired actomyosin interaction is the primary defect at molecular level leading to HCM associated with this mutation.
α-cardiac actin mutations in DCM
Two missense mutations, R312H and E361G, have been identified in ACTC1 as a cause of DCM with apparently favorable prognosis. 59 R312H occurs at the residue next to D311 in subdomain 3 that forms an attractive electrostatic interaction with TM in the high Ca 2+ state.
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E361G occurs in a binding domain for α-actinin in subdomain 1, which anchors thin filaments to Z-discs and intercalated discs. 61 Wong et al. reported that this mutation had no effects on actin polymerization, rigor binding, actomyosin ATPase, and in vitro motility, but slightly reduced the affinity of actin filament for α-actinin, 56 suggesting that impaired force transmission via Z-discs and intercalated discs might be responsible for the pathogenesis. Vang et al. reported that these two mutations impaired the protein-folding pathway and filament formation, as were the cases with HCM-causing mutations. 
Mutations in genes for the thick filament proteins
Myosin
Cardiac muscle expresses two isoforms, α-and β-cardiac MyHCs. The α-MyHC is abundant in both atria and ventricles during mammalian embryogenesis. In small mammals, including mouse and rat, α-MyHC remains a predominant isoform expressed in both atria and ventricles during adulthood. 62 In contrast, β-MyHC is expressed predominantly in the ventricles and α-MyHC in the atria during adulthood in large mammals, including rabbit and human. The β-cardiac MyHC is also known to be expressed in slow skeletal muscle, type I fibers.
β-MyHC mutations in HCM
Mutations in the β-MyHC gene (MYH7) are the most frequent causes of HCM, with at least studied calcium cycling in intact cardiac muscle fibers and reported that mutant myofilaments were more sensitive to Ca 2+ below half-maximal [Ca 2+ ] i and lead to a diastolic dysfunction. 67 Warshaw and colleagues investigated cardiac myosin isolated from homozygous mice and reported that R403Q enhanced the force generating capacity and actomyosin ATPase activity as well as the velocity of actin filament sliding, whereas R453C enhanced only the force generating capacity. 68, 69 Although the reason for the discrepancy from the previous studies remains unclear, 70 they proposed that the HCM-causing mutations should augment the power output of the hearts beyond the mechanical stress tolerance of a normal cardiac sarcomere, which might be a primary stimulus for the hypertrophic response. 68 Marian et al. created a transgenic rabbit model expressing human β-MyHC R403Q mutant. 71 These rabbits exhibited the phenotype virtually identical to that of human HCM, i.e., premature death, cardiac hypertrophy, myocyte disarray, interstitial fibrosis, and normal systolic function, so that this model promises to be an important resource for pathogenic and therapeutic studies of human HCM.
β-MyHC mutations in DCM
Eleven missense mutations have been found in MYH7 as a cause of DCM ( 
Essential myosin light chain mutations in HCM
Mutations in the ventricular essential myosin light chain (ELC) gene (MYL3) is a rare cause of HCM (<1%), with only four missense mutations being identified (Table 1 ). M149V was found in a large family, of which 6 had a rare phenotype, as a familial condition, involving mid left ventricular chamber thickening. 73 Low mortality rate in this family suggests M149V is associated with a benign prognosis. Transgenic mice expressing human ventricular ELC with M149V faithfully recapitulated the cardiac disease of the patients with this mutation at old age (>1 year) (i.e., an unusual phenotype of mid-cavitary obstruction). 74 Transgenic mice expressing "mouse" ventricular ELC with M158V, corresponding to M149V in human, developed no hypertrophy, even in senescent animals (1.5 years). 75 Transgenic rabbits expressing rabbit ventricular ELC with M154V, corresponding to M149V in human, again showed no discernible pattern of disease at the structural or functional levels except for a very subtle increase in the myofilament Ca 2+ sensitivity, suggesting that this mutation is not causative for HCM at least in rabbit, although it remains possible that a phenotype might present in older rabbits. 
Regulatory myosin light chain mutations in HCM
Eight missense mutations and two splice site mutations have been found in the ventricular regulatory myosin light chain (RLC) gene (MYL2) as a cause of HCM (Table 1 ). The MYL2 gene has been shown to be common in HCM families with a malignant prognosis. 77 Szczesna-Cordary et al. created transgenic mice expressing E22K, N47K and R58Q human ventricular RLC. 78 These mice showed no cardiac hypertrophy. Nevertheless, cardiac myofibrils or skinned fibers prepared from E22K and N47K but not from R58Q mice showed increased single-turnover contraction in cardiac myofibrils from mutant mice and reported that E22K had no effect on the mechanical properties of crossbridges. mutations is associated with later onset, less hypertrophy, lower penetrance, and a better prognosis compared with mutations in MYH7 or TNNT2.
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Transgenic mice expressing a mutant cMyBP-C lacking its C-terminal half, which mimicked the truncation mutations in HCM, showed no significant cardiac hypertrophy and no significantly increased morbidity or mortality. 81 The truncated protein was not correctly incorporated into the A-band of the sarcomere, suggesting that haplo-insufficiency might play a role in the pathogenic process. Homozygous knockout mice were also viable and displayed well-developed sarcomeres but exhibited significant cardiac hypertrophy with reduced diastolic function. These data demonstrated that cMyBP-C is not essential for forming and maintaining sarcomere ultrastructure but that the absence of cMyBP-C results in cardiac hypertrophy and dysfunction. 
Mutations in genes for titin and Z-disc proteins
Titin
In the titin gene (TTN), two missense mutations have been identified as a cause of HCM, 4 Titin is encoded by a single gene TTN and differential splicing of exons encoding the central I-band region produces muscle type-specific isoforms.
The affinity of titin Z1-Z2 domains for T-cap (or telethonin) is decreased by DCM-causing mutation V154M. 83 The affinity of the titin Z-repeat region for α-actinin is increased by HCM-causing R740L while decreased by DCM-causing A743V, 83, 84 suggesting that opposite effects on the integrity of titin in the Z-disc might explain the distinct phenotypes caused by these mutations. DCM-causing S3799Y increases the affinity of the titin N2B region for four and half LIM protein 2, 85 known to bind metabolic enzymes, 86 suggesting that altered recruitment of metabolic enzymes to the sarcomere may play a role in the pathogenesis of cardiomyopathies.
Z-disc proteins
T-cap binds to the N-terminus of titin at the Z-disc. T-cap interaction with titin is stabilized by another Z-disc protein, muscle LIM protein (MLP), and MLP/T-cap/titin complex are thought to serve as a mechanical stress sensor. 87 Four missense mutations have been identified in the 90 Only one missense mutation, K69R, in CSRP3 has been identified as a cause of familial DCM. 91 This mutation is in a nuclear localization signal adjacent to the LIM1 domain of MLP.
A missense mutation, S48P, in the myozenin-2 gene (MYOZ2) has been found in a large family with HCM characterized by early onset of symptoms, pronounced cardiac hypertrophy, and cardiac arrhythmias.
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A missense mutation, Q9R, in the α-actinin gene (ACTN2) has been found in a patient with DCM and reported to disturb the interaction of α-actinin with MLP. 
Conclusion
Functional studies that have so far been made on sarcomeric regulatory proteins shows that HCM or RCM-causing mutations increase the Ca 2+ sensitivity of cardiac myofilaments, whereas DCM-causing mutations decrease it. Increased Ca 2+ sensitivity of cardiac myofilaments is also caused by HCM-causing mutations in the thick filament proteins; this is not surprising because it is well known that there exists a positive feedback mechanism between troponin Ca 2+ binding and myosin crossbridge attachment. Increased myofilament Ca 2+ sensitivity is expected to increase the ATP utilization by actomyosin at submaximal Ca 2+ concentrations, which might cause an imbalance in energy supply and demand in the heart under severe stress. NMR studies have revealed that myocardial energetics is compromised in mouse models of HCM caused by R92Q mutation in cTnT and R403Q mutation in α-MyHC, 96, 97 as is the case with human patients affected by mutations in sarcomeric proteins, including cTnT. 98 Chandra et al. reported that the skinned cardiac muscle fibers from transgenic mice with HCM-causing ΔE160 mutation in cTnT showed an increased ATP-consumption of force maintenance (i.e., increased tension cost).
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Based on the similarity of the clinical phenotypes of diseases that limit myocardial energy production to those of HCM, Ashrafian et al. have proposed that the increased energy demand owing to inefficient sarcomeric ATP utilization in HCM compromises the contraction and homeostatic functions of the cardiac myocyte, leading to myocyte hypertrophy. 99 The increase and decrease in the myofilament Ca 2+ sensitivity well account for the diastolic and systolic dysfunction of model animals as well as human patients of HCM and DCM, respectively. Diastolic and systolic dysfunction should increase and decrease the ventricular wall stress, which could be transmitted to the biomechanical sensor in Z-discs or intercalated discs controlling gene expression and lead to HCM (or RCM) and DCM, respectively. Further studies on the detailed pathogenic mechanisms involving the huge numbers of mutations of sarcomeric proteins found in cardiomyopathies will contribute to clarifying the entire feature of the physiological mechanisms controlling cardiac function and structure.
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